Congresses

Titlesort descending Year
IMPLEMENTATION OF THE HOLLOW FIBER SYSTEM FOR ANTIMICROBIAL RESEARCH 2020
OPTIKA, a new high content in vitro kill-kinetic assay to evaluate the efficacy of novel anti-TB drug combinations 2022
A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens 2022
A new weapon against Mycobacterium abscessus 2022
A novel methodology to identify synergistic drug combinations against non-tuberculous mycobacteria in cystic fibrosis 2019
Anthelmintic avermectins for the treatment of non-tuberculous mycobacteria infections in cystic fibrosis 2018
ANTHELMINTIC AVERMECTINS FOR THE TREATMENT OF NON-TUBERCULOUS MYCOBACTERIA INFECTIONS IN CYSTIC FIBROSIS 2018
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
Beta-lactams for Tuberculosis Treatment 2019
Caracterización biológica de una nueva serie de compuestos químicos con actividad antimicrobiana 2018
Clinical trial design optimisation and dose rationale for the treatment of Buruli ulcer antibiotic combination therapy 2021
DEVELOPMENT OF A HIGH-THROUGHPUT METHOD FOR SYNERGISTIC DRUG COMBINATIONS SCREENING 2019
Development of a high-throughput method for synergistic drug combinations screening 2018
Development Of An Efficient In Vitro High-Throughput Method To Discover New Combinatorial Therapies Against Non-Tuberculous Mycobacteria 2020
Discovering the mode of action of a novel chemical series active against mycobacteria and other microbial pathogens 2020
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
Discovery of new therapies for Buruli ulcer treatment 2017
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021

Pages